Clinical trial NCT04228237: LUng CAncer focuS - Long-term Monitoring of Bronchogenic Carcinoma Patients (LUCAS)
Official title: LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS)
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Lung Cancer
Keywords: lung cancer
bronchogenic carcinoma
diagnosis
treatment
non-interventional
Lead sponsor: Ceska Lekarska Spolecnost Jana Evangelisty Purkyne z.s.
Sponsor class: OTHER
Collaborators: name: OAKS Consulting s.r.o.
First posted: 2020-01-14
Enrollment: 2300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: all newly diagnosed patients in participating pulmonology centers

Brief summary: Long-term non-interventional monitoring of diagnostics and treatment patterns in newly diagnosed patients in selected pneumology centers in Czech republic.

Detailed description: Diagnosis, treatment and care of patients with bronchogenic carcinoma (BCA) is, as with most other oncological diseases, a complex multidisciplinary process. Due to the lack of information on the speed and success of the initial diagnosis, the use of the necessary laboratory techniques, and the individual therapeutic steps leading to cure or medical failure, the Czech Pneumological and Phtizeology Society (CPPS) decided to carry out long-term non-interventional monitoring of newly diagnosed patients.

This monitoring is non-interventional, so the usual diagnostic and therapeutic procedures will be used according to the decision of the physician. All patients with bronchogenic carcinoma diagnosed from June 1, 2018 will be enrolled with up to 60 months of follow-up.

Eligibility criteria: Inclusion Criteria:

- clinical diagnosis of lung cancer (C34 in MKN classification)

Exclusion Criteria:

Primary outcomes:
measure: Overall survival (OS)
timeFrame: 60 months of follow-up
measure: Progression-free survival (PFS)
timeFrame: any treatment during 60 months of follow-up
measure: Time to treatment discontinuation (TTD)
timeFrame: any treatment during 60 months of follow-up
Secondary outcomes:
measure: Time to next treatment (TTNT)
timeFrame: 60 months of follow-up
Other outcomes:
Locations:
city: Brno
country: Czechia
facility: University hospital Brno
city: Hradec Kralove
country: Czechia
facility: University hospital Hradec Kralove
city: Olomouc
country: Czechia
facility: University hospital Olomouc
city: Plzen
country: Czechia
facility: University hospital Plzen
city: Prague
country: Czechia
facility: University Thomayer hospital
city: Praha 5
country: Czechia
facility: University hospital Motol
city: Praha 8
country: Czechia
facility: University hospital Bulovka
state: Česká Republika
Study officials:
affiliation: University Thomayer hospital Prague
name: Martina Koziar Vasakova, Prof.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Venclicek O, Skrickova J, Brat K, Fischer O, Havel L, Hrnciarik M, Marel M, Opalka P, Krakorova G, Rozsivalova D, Kultan J, Mullerova A, Zarnayova L, Smickova P, Vasakova M, Gyorfy Z, Jirousek M, Krejci D, Krejci J, Zuna P, Svaton M, Hrda K, Duba J, Alahakoon J, Svoboda M, Silar J. Lung Cancer in Non-smokers in Czech Republic: Data from LUCAS Lung Cancer Clinical Registry. Anticancer Res. 2021 Nov;41(11):5549-5556. doi: 10.21873/anticanres.15368.